Concepts (136)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Burns | 2 | 2021 | 21 | 0.970 |
Why?
|
| Immunoglobulin G | 3 | 2022 | 129 | 0.940 |
Why?
|
| Simian Immunodeficiency Virus | 2 | 2021 | 22 | 0.920 |
Why?
|
| CA-125 Antigen | 2 | 2020 | 3 | 0.880 |
Why?
|
| Vaccines | 1 | 2022 | 12 | 0.880 |
Why?
|
| Membrane Proteins | 2 | 2020 | 173 | 0.790 |
Why?
|
| Epitopes | 1 | 2020 | 81 | 0.720 |
Why?
|
| Immunoglobulins, Intravenous | 2 | 2021 | 16 | 0.660 |
Why?
|
| Carbocyanines | 1 | 2017 | 3 | 0.620 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2017 | 78 | 0.610 |
Why?
|
| Fluorescent Dyes | 1 | 2017 | 54 | 0.610 |
Why?
|
| Microscopy, Fluorescence | 1 | 2017 | 85 | 0.610 |
Why?
|
| Antibodies, Viral | 5 | 2022 | 87 | 0.550 |
Why?
|
| HIV Antibodies | 3 | 2021 | 42 | 0.390 |
Why?
|
| Mucous Membrane | 3 | 2021 | 40 | 0.380 |
Why?
|
| HIV Infections | 3 | 2021 | 980 | 0.320 |
Why?
|
| Animals | 7 | 2021 | 4577 | 0.270 |
Why?
|
| HIV-1 | 2 | 2021 | 440 | 0.260 |
Why?
|
| Glycosylation | 2 | 2022 | 24 | 0.260 |
Why?
|
| Macaca mulatta | 3 | 2021 | 65 | 0.250 |
Why?
|
| Humans | 14 | 2022 | 29361 | 0.250 |
Why?
|
| Antibody Formation | 1 | 2022 | 40 | 0.220 |
Why?
|
| Cysteine Endopeptidases | 2 | 2012 | 9 | 0.210 |
Why?
|
| Organizations | 1 | 2021 | 3 | 0.210 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2012 | 55 | 0.210 |
Why?
|
| Immunoglobulin A, Secretory | 1 | 2021 | 6 | 0.200 |
Why?
|
| Rectum | 2 | 2021 | 61 | 0.200 |
Why?
|
| Simian Acquired Immunodeficiency Syndrome | 1 | 2021 | 22 | 0.200 |
Why?
|
| Health Personnel | 1 | 2021 | 115 | 0.190 |
Why?
|
| Vagina | 2 | 2017 | 46 | 0.190 |
Why?
|
| Mucins | 1 | 2020 | 6 | 0.190 |
Why?
|
| AIDS Vaccines | 1 | 2020 | 14 | 0.180 |
Why?
|
| Delivery of Health Care | 1 | 2021 | 152 | 0.180 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 2020 | 28 | 0.180 |
Why?
|
| Intestinal Mucosa | 2 | 2012 | 220 | 0.180 |
Why?
|
| Colon | 1 | 2021 | 148 | 0.180 |
Why?
|
| Surface Plasmon Resonance | 1 | 2017 | 7 | 0.160 |
Why?
|
| Cervix Mucus | 1 | 2017 | 4 | 0.160 |
Why?
|
| Drug Stability | 1 | 2017 | 9 | 0.160 |
Why?
|
| Protein Stability | 1 | 2017 | 7 | 0.160 |
Why?
|
| Tissue Distribution | 1 | 2017 | 42 | 0.150 |
Why?
|
| Plasma | 1 | 2017 | 34 | 0.150 |
Why?
|
| Infusions, Intravenous | 1 | 2017 | 76 | 0.150 |
Why?
|
| Models, Animal | 1 | 2017 | 126 | 0.150 |
Why?
|
| Survivors | 1 | 2017 | 57 | 0.150 |
Why?
|
| Sleep Wake Disorders | 1 | 2017 | 148 | 0.130 |
Why?
|
| Bacteriophages | 1 | 2012 | 1 | 0.110 |
Why?
|
| Ubiquitin | 1 | 2012 | 24 | 0.110 |
Why?
|
| Trinitrobenzenesulfonic Acid | 1 | 2012 | 1 | 0.110 |
Why?
|
| Dextran Sulfate | 1 | 2012 | 11 | 0.110 |
Why?
|
| Colitis | 1 | 2012 | 37 | 0.110 |
Why?
|
| Spike Glycoprotein, Coronavirus | 2 | 2022 | 17 | 0.100 |
Why?
|
| Quality of Life | 1 | 2017 | 664 | 0.100 |
Why?
|
| Antibodies, Neutralizing | 2 | 2022 | 27 | 0.100 |
Why?
|
| Tight Junctions | 1 | 2011 | 28 | 0.100 |
Why?
|
| Surveys and Questionnaires | 1 | 2017 | 1184 | 0.100 |
Why?
|
| Female | 5 | 2022 | 16211 | 0.100 |
Why?
|
| Nuclear Proteins | 1 | 2011 | 89 | 0.100 |
Why?
|
| Transfer RNA Aminoacylation | 1 | 2009 | 1 | 0.090 |
Why?
|
| Methionine | 1 | 2009 | 3 | 0.090 |
Why?
|
| Oxidative Stress | 1 | 2009 | 124 | 0.090 |
Why?
|
| Immunity, Innate | 1 | 2009 | 90 | 0.090 |
Why?
|
| Cytokines | 2 | 2012 | 348 | 0.080 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 2005 | 17 | 0.070 |
Why?
|
| Respiratory Hypersensitivity | 1 | 2005 | 5 | 0.070 |
Why?
|
| Th2 Cells | 1 | 2005 | 27 | 0.070 |
Why?
|
| Promoter Regions, Genetic | 1 | 2005 | 80 | 0.070 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2005 | 306 | 0.060 |
Why?
|
| Young Adult | 2 | 2022 | 1935 | 0.060 |
Why?
|
| Antibodies | 1 | 2022 | 65 | 0.050 |
Why?
|
| Immunotherapy | 1 | 2022 | 62 | 0.050 |
Why?
|
| Mice | 3 | 2012 | 1620 | 0.050 |
Why?
|
| Tumor Necrosis Factor alpha-Induced Protein 3 | 2 | 2012 | 3 | 0.050 |
Why?
|
| Nigeria | 1 | 2022 | 4 | 0.050 |
Why?
|
| Africa, Western | 1 | 2022 | 4 | 0.050 |
Why?
|
| Genome, Viral | 1 | 2022 | 12 | 0.050 |
Why?
|
| Mass Spectrometry | 1 | 2021 | 41 | 0.050 |
Why?
|
| Phylogeny | 1 | 2022 | 63 | 0.050 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2021 | 21 | 0.050 |
Why?
|
| Mice, Transgenic | 2 | 2012 | 250 | 0.050 |
Why?
|
| Severity of Illness Index | 2 | 2017 | 1113 | 0.050 |
Why?
|
| Mutation | 1 | 2022 | 383 | 0.050 |
Why?
|
| Child, Preschool | 1 | 2022 | 641 | 0.050 |
Why?
|
| Child | 1 | 2022 | 1345 | 0.040 |
Why?
|
| Injury Severity Score | 1 | 2017 | 15 | 0.040 |
Why?
|
| Sickness Impact Profile | 1 | 2017 | 19 | 0.040 |
Why?
|
| China | 1 | 2017 | 59 | 0.040 |
Why?
|
| Adult | 2 | 2022 | 8604 | 0.040 |
Why?
|
| Antibody Affinity | 1 | 2016 | 3 | 0.040 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2016 | 9 | 0.040 |
Why?
|
| Mucus | 1 | 2016 | 8 | 0.040 |
Why?
|
| Protein Binding | 1 | 2016 | 127 | 0.030 |
Why?
|
| Adolescent | 1 | 2022 | 2280 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2017 | 330 | 0.030 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2012 | 45 | 0.030 |
Why?
|
| Male | 2 | 2022 | 15637 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2017 | 1442 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 2012 | 193 | 0.030 |
Why?
|
| Time Factors | 1 | 2017 | 1618 | 0.030 |
Why?
|
| Models, Molecular | 1 | 2012 | 81 | 0.030 |
Why?
|
| Kinetics | 1 | 2012 | 225 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2022 | 4851 | 0.030 |
Why?
|
| HCT116 Cells | 1 | 2011 | 10 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2017 | 1829 | 0.030 |
Why?
|
| NF-kappa B | 1 | 2012 | 107 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2017 | 1812 | 0.030 |
Why?
|
| Cell Line | 1 | 2011 | 299 | 0.020 |
Why?
|
| Apoptosis | 1 | 2012 | 251 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2011 | 391 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2011 | 215 | 0.020 |
Why?
|
| Risk Factors | 1 | 2017 | 2446 | 0.020 |
Why?
|
| RNA, Transfer, Met | 1 | 2009 | 1 | 0.020 |
Why?
|
| Genetic Code | 1 | 2009 | 2 | 0.020 |
Why?
|
| Orthomyxoviridae | 1 | 2009 | 3 | 0.020 |
Why?
|
| Adenoviridae | 1 | 2009 | 20 | 0.020 |
Why?
|
| Substrate Specificity | 1 | 2009 | 26 | 0.020 |
Why?
|
| HeLa Cells | 1 | 2009 | 50 | 0.020 |
Why?
|
| Ligands | 1 | 2009 | 55 | 0.020 |
Why?
|
| Models, Genetic | 1 | 2009 | 36 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2011 | 255 | 0.020 |
Why?
|
| Toll-Like Receptors | 1 | 2009 | 28 | 0.020 |
Why?
|
| NADPH Oxidases | 1 | 2009 | 43 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2009 | 126 | 0.020 |
Why?
|
| Middle Aged | 1 | 2022 | 9823 | 0.020 |
Why?
|
| Aged | 1 | 2022 | 9447 | 0.020 |
Why?
|
| Inducible T-Cell Co-Stimulator Protein | 1 | 2005 | 2 | 0.020 |
Why?
|
| 5' Untranslated Regions | 1 | 2005 | 2 | 0.020 |
Why?
|
| Immunoglobulin E | 1 | 2005 | 15 | 0.020 |
Why?
|
| Homozygote | 1 | 2005 | 23 | 0.020 |
Why?
|
| Binding Sites | 1 | 2005 | 71 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2005 | 97 | 0.020 |
Why?
|
| Alleles | 1 | 2005 | 224 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2005 | 265 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2005 | 174 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2005 | 676 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2005 | 441 | 0.010 |
Why?
|